117 related articles for article (PubMed ID: 10070950)
1. Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Samid D
J Natl Cancer Inst; 1999 Mar; 91(5):475-6. PubMed ID: 10070950
[No Abstract] [Full Text] [Related]
2. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Warrell RP; He LZ; Richon V; Calleja E; Pandolfi PP
J Natl Cancer Inst; 1998 Nov; 90(21):1621-5. PubMed ID: 9811311
[TBL] [Abstract][Full Text] [Related]
3. Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells.
Merzvinskyte R; Treigyte G; Savickiene J; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2006 Dec; 1091():356-67. PubMed ID: 17341628
[TBL] [Abstract][Full Text] [Related]
4. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
5. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
[TBL] [Abstract][Full Text] [Related]
7. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
[TBL] [Abstract][Full Text] [Related]
8. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
[TBL] [Abstract][Full Text] [Related]
9. Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Warrell RP
Haematologica; 1999 Jun; 84 Suppl EHA-4():75-7. PubMed ID: 10907475
[No Abstract] [Full Text] [Related]
10. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
11. Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia.
Cunha De Santis G; Tamarozzi MB; Sousa RB; Moreno SE; Secco D; Garcia AB; Lima AS; Faccioli LH; Falcão RP; Cunha FQ; Rego EM
Haematologica; 2007 Dec; 92(12):1615-22. PubMed ID: 18055984
[TBL] [Abstract][Full Text] [Related]
12. [Recent advances of differentiation-inducing therapy for leukemia].
Kizaki M
Rinsho Ketsueki; 2000 Mar; 41(3):173-6. PubMed ID: 10774243
[No Abstract] [Full Text] [Related]
13. [Histone deacetylase-targeted anti-leukemia therapy].
Ozawa Y
Rinsho Ketsueki; 2002 Apr; 43(4):231-4. PubMed ID: 12043197
[No Abstract] [Full Text] [Related]
14. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of histone-deacetylases.
Pelicci PG
Tumori; 2001; 87(6):S12-4. PubMed ID: 11989609
[No Abstract] [Full Text] [Related]
16. Acute promyelocytic leukemia: retinoic acid response and resistance.
Early E; Dmitrovsky E
J Investig Med; 1995 Aug; 43(4):337-44. PubMed ID: 7552583
[No Abstract] [Full Text] [Related]
17. Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
McMullin MF; Nugent E; Thompson A; Hull D; Jones FG; Grimwade D
Leukemia; 2005 Sep; 19(9):1676-7. PubMed ID: 16034463
[No Abstract] [Full Text] [Related]
18. [Pathogenesis of acute promyelocytic leukemia].
Tokuhira M; Kizaki M
Nihon Rinsho; 2012 Apr; 70 Suppl 2():409-14. PubMed ID: 23133991
[No Abstract] [Full Text] [Related]
19. Histone deacetylase inhibitors in APL and beyond.
Petrie K; Prodromou N; Zelent A
Curr Top Microbiol Immunol; 2007; 313():157-203. PubMed ID: 17217044
[TBL] [Abstract][Full Text] [Related]
20. Development and overcoming of ATRA resistance in acute promyelocytic leukemia.
Lo Coco F
Haematologica; 1999 Nov; 84(11):961-2. PubMed ID: 10553153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
